- Home
- MAPS vs TCRX Comparison
MAPS vs TCRX Comparison
Compare MAPS & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MAPS | TCRX |
|---|---|---|
| Founded | 2008 | 2018 |
| Country | United States | United States |
| Employees | 449 | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 70.7M | 63.6M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | MAPS | TCRX |
|---|---|---|
| Price | $0.66 | $1.01 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $2.61 | ★ $7.00 |
| AVG Volume (30 Days) | ★ 685.1K | 574.3K |
| Earning Date | 03-12-2026 | 03-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 12.28 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $10,325,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.17 | $19.81 |
| P/E Ratio | $9.75 | ★ N/A |
| Revenue Growth | N/A | ★ 266.65 |
| 52 Week Low | $0.60 | $0.88 |
| 52 Week High | $1.36 | $2.57 |
Technical Indicators
Market Signals| Indicator | MAPS | TCRX |
|---|---|---|
| Relative Strength Index (RSI) | 47.80 | 45.55 |
| Support Level | $0.65 | $0.90 |
| Resistance Level | $0.88 | $1.24 |
| Average True Range (ATR) | 0.04 | 0.06 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 36.79 | 34.91 |
Price Performance
Historical ComparisonAbout MAPS WM Technology Inc.
WM Technology Inc operates an online cannabis marketplace for consumers, together with a comprehensive set of e-commerce and compliance software solutions for cannabis businesses, which are sold to both storefront locations and delivery operators (retailers) and brands in the legalized cannabis markets in states and territories of the United States. Its comprehensive business-to-consumer and business-to-business suite of products affords cannabis retailers and brands of all sizes integrated tools to compliantly run their businesses and to reach, convert, and retain consumers.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.